A study conducted by Cognito Therapeutics Inc. demonstrated significant changes in white matter volume and myelination in patients with Alzheimer’s disease after six months of at-home, non-invasive gamma stimulation therapy in a presentation at the Alzheimer’s Association International Conference 2023.
Neuren Pharmaceuticals Ltd. and Acadia Pharmaceuticals Inc. have expanded their development and commercialization partnership for Daybue (trofinetide) beyond the U.S. to take the Rett syndrome treatment to the world in a deal valued at $527 million plus royalties.
Researchers from Anhui Medical University (AMU) and Wuhan University of Technology (WUT) presented the discovery of novel acetylcholinesterase (AChE) inhibitors as potential disease-modifying anti-Alzheimer’s disease (AD) candidates.
Spinocerebellar ataxia type 3 (SCA3) is the most common autosomal dominant hereditary ataxia worldwide, with no cure available. Intranuclear aggregation of the mutant expanded ATXN3 protein is a neuropathological hallmark of SCA3 linked to neurotoxicity.
Aeterna Zentaris Inc. has offered an update on its development pipeline programs. Macimorelin acetate (AEZS-130), a ghrelin agonist approved and commercialized as a test for adult growth hormone deficiency, is in preclinical development for amyotrophic lateral sclerosis (ALS). The company has now successfully developed an alternative formulation suitable for use in ALS.
Given that monoclonal antibodies are so big, only 0.1% of a dose will cross the blood-brain barrier (BBB). And that’s why their utility in central nervous system (CNS) disorders management is limited.
Questionable efficacy, high priced and risky side effects are some words to describe Leqembi (lecanemab), the latest amyloid beta-targeting antibody approved by the U.S. FDA, Korean experts said, but none of that diminishes the profound significance of the drug for Alzheimer’s disease.
Delix Therapeutics Inc. has identified pyrrolidine psychoplastogens acting as 5-HT2A receptor modulators reported to be useful for the treatment of neurodegeneration, substance abuse and dependence, impulse control, mood, sleep, anxiety, eating and personality disorders, among others.
Raya Therapeutic Inc. has entered into an early-stage R&D collaboration with Argenx SE to evaluate combinations of Raya’s pipeline of targeted small molecules with a potentially complementary product from Argenx.
RSS
